BriaCell Therapeutics Corp. BCTXF Archives - Page 6 of 6

FridayOct 12, 2018 12:10 pm

Sugarmade, Inc. (SGMD) Sees Significant Future Revenue Growth, Cost Synergies with Targeted Acquisition Proposals

If successful, acquisition of two profitable hydroponic cultivation supply companies will boost Sugarmade’s 2019 revenue guidance to $75 million Global hydroponics market expected to be worth more than $10 billion by 2023 Expansion into hemp market includes significant investment into hemp cultivation Hemp-derived cannabidiol market worth $591 million, expected to hit $22 billion in under five years Sugarmade, Inc. (OTCQB: SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is seeking to expand its portfolio with the acquisition of two hydroponic cultivation companies working in the lucrative cannabis space. Bringing the two companies into…

FridayOct 12, 2018 11:42 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Initiates Patient Dosing in Phase I/IIa Combination Study Targeting Advanced Breast Cancer

Patient dosing has commenced in a combination study of Bria-IMT with KEYTRUDA or YERVOY in advanced breast cancer Company recently announced positive proof of concept data in the Phase I/IIa study of Bria-IMT in advanced breast cancer patients, which indicated excellent targeted anti-tumor activity and outstanding safety and tolerability KEYTRUDA and YERVOY are highly recognized for their potent immune boosting properties, which validates BriaCell's strategy to use these therapeutics in its combination study BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company engaged in developing targeted and safe approaches for cancer management, recently announced (http://ibn.fm/Hej9T) that it has initiated patient dosing in…

TuesdayOct 09, 2018 10:17 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Initiates Patient Dosing in Combination Study of Bria-IMT

BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced that it has initiated patient dosing in a phase I/IIa study of its lead clinical candidate, Bria-IMT, in combination with pembrolizumab [KEYTRUDA; manufactured by Merck & Co., Inc. (NYSE: MRK)] or ipilimumab [YERVOY; manufactured by Bristol-Myers Squibb Company (NYSE: BMY)]. “We believe that combination of Bria-IMT with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with KEYTRUDA or YERVOY,” Bill Williams, president and CEO of BriaCell, stated…

FridayOct 05, 2018 12:53 pm

BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Lead Candidate Shows Promising Anti-Tumor Activity in Proof of Concept Study

Company achieves positive proof of concept in Phase IIa study of its lead product candidate, Bria-IMT, in advanced breast cancer patients Efficacy data comparable to that of other approved breast cancer therapies in a similar stage of development Combination study with immune checkpoint inhibitors in the works, enrollment already open BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company focused on the development of proprietary targeted immunotherapy for advanced breast cancer, has achieved proof of concept and reported promising results from a Phase IIa study of its lead clinical candidate, Bria-IMT. Study data indicates promising anti-tumor activity for…

TuesdayOct 02, 2018 3:17 pm

QualityStocksNewsBreaks – Why BriaCell Therapeutics Corp. (TSX-V: BCT) (OTCQB: BCTXF) is “One to Watch”

BriaCell Therapeutics (TSX-V: BCT) (OTCQB: BCTXF) is an immuno-oncology focused clinical-stage biotechnology company developing a proprietary targeted immunotherapy technology for advanced breast cancer. A recent article discussing the company reads: “The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX as…

MondayOct 01, 2018 10:35 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Scientific Findings at New York Conferences

BriaCell is set to present clinical and scientific data on its findings in biomarker analyses from the clinical trials it has so far conducted; the presentations will take place at the upcoming conferences in New York The clinical efficacy data, which will be made public in advance of these conferences, is crucial to BriaCell, because it helps advance the company’s BriaDX diagnostic test solution; BriaDX is used in determining the kind of patients with a high likelihood of responding to advanced breast cancer treatment BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is a clinical-stage biotechnology company based in Berkeley, California.…

ThursdaySep 27, 2018 3:36 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) CEO Presents Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer

BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Wednesday announced that it achieved proof of concept in the Phase IIa study of its lead clinical candidate, Bria-IMT(Trademarked), in advanced breast cancer. The company followed the after-hours news with a live webcast discussing the results, as presented by the company’s CEO Dr. Bill Williams. The data demonstrates promising anti-tumor activity of Bria-IMT in heavily pre-treated advanced breast cancer patients. BriaCell is now focusing on the combination study of Bria-IMT with pembrolizumab (Keytruda®, manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®, manufactured by Bristol-Myers Squibb Company) in patients with advanced breast cancer.…

WednesdaySep 26, 2018 3:08 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Achieves Proof of Concept in Bria-IMT Monotherapy Study; Hosting Webcast to Further Discuss Results

BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announced that it has achieved proof of concept in the Phase IIa study of its lead clinical candidate, Bria-IMT™, in advanced breast cancer. The data demonstrates promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients. The company is focusing on the combination study of the candidate with pembrolizumab (Keytruda®; manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®; manufactured by Bristol-Myers Squibb Company) to boost the anti-tumor activity of Bria-IMT™. Given the conclusive findings of the first 20 patients…

FridaySep 21, 2018 9:40 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) to Present Clinical Trial Data at Two Upcoming NYC Conferences

BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced that it will be presenting data from biomarker analyses of its clinical trials for advanced breast cancer at the Fourth International Cancer Immunotherapy Conference, as well as at The MicroCap Conference. Both events will take place in New York City. The first presentation, at the Fourth International Cancer Immunotherapy Conference, will take place on Sunday, September 30 at 11:45 am. The second, at The MicroCap Conference, will take place on Monday, October 1 at 4:30 pm. Per the update,…

TuesdaySep 18, 2018 8:56 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is “One to Watch”

Developing the first off-the-shelf personalized immunotherapy for advanced breast cancer, Bria-OTS. Bria-OTS is designed to provide personalized treatment for ~90% of the advanced breast cancer patients without the high costs and difficult manufacturing associated with personalized treatments. The technology may be applicable to other cancers. Addressing an unmet need by targeting advanced breast cancer, from which an estimated 40,000 women have died in U.S. in 2017 $1 billion-$5 billion market opportunity depending on patient treatment stage Results of two completed proof-of-concept human clinical trials showed rapid tumor shrinkage at multiple sites in advanced breast cancer patients without toxicity associated with…

Site Search

Company Search

Tag: BriaCell Therapeutics Corp. BCTXF